A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

The company behind weight-loss jab Wegovy and diabetes drug Ozempic will have a boardroom clear-out, with seven board members ...

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and ...

The Novo Nordisk Foundation plans to replace the board with a slate of directors led by the foundation’s chair, Lars Rebien ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

Novo Nordisk is striving to maintain Medicaid reimbursement for its obesity drug, Wegovy, as several U.S. states face ...